Literature DB >> 22404076

Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy.

R P Parry1, K I Tettmar, K Hoschler, S R Brailsford, D Samuel, M Ashford, S Maclennan, L M Williamson, R S Tedder.   

Abstract

BACKGROUND AND OBJECTIVES: During the 1918, pandemic blood components were successfully used to treat severe influenza pneumonia. A Proof of Principle trial investigating the clinical benefit of convalescent plasma was proposed in the 2009 H1N1v epidemic with the aim of screening donors for high titre antibody in order to stockpile plasma packs to be used for treatment for severe pneumonia.
MATERIALS AND METHODS: Serum samples were collected from donors. IgG antibody capture format enzyme-linked immunoassays using recombinant proteins (GACELISAs) were compared with microneutralization (MN) and haemagglutination inhibition (HAI). The influence of age and history of influenza-like illness (ILI) on the detection of high titre antibody was examined.
RESULTS: 1598 unselected donor sera collected in October and December 2009 were tested by HAI. The HAI and demographic data defined a possible strategy for selective donor screening. One of the GACELISAs was highly specific for recent infection but showed lower sensitivity than HAI.
CONCLUSIONS: During the 2009 pandemic screening 17- to 30-year-old donors by HAI delivered around 10% with high antibody levels. The ELISA using a short recombinant H1N1v HA detected fewer reactives but was more specific for high titre antibody (≥1:256). Screening strategies are proposed based on using HAI on serum or GACELISA on plasma.
© 2012 The Author(s). Vox Sanguinis © 2012 International Society of Blood Transfusion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22404076     DOI: 10.1111/j.1423-0410.2012.01599.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  6 in total

1.  Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China.

Authors:  Xingui Tian; Zaixue Jiang; Qiang Ma; Qian Liu; Xiaomei Lu; Wenkuan Liu; Xiaohong Liao; Rong Zhou; Xiaobo Su; Qingming Luo
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone.

Authors:  Richard S Tedder; Dhan Samuel; Steve Dicks; Janet T Scott; Samreen Ijaz; Catherine C Smith; Charlene Adaken; Christine Cole; Samuel Baker; Tansy Edwards; Philip Kamara; Osman Kargbo; Saidia Niazi; Davis Nwakanma; Umberto d'Alessandro; Graham Burch; Heidi Doughty; Colin S Brown; Nick Andrews; Judith R Glynn; Johan van Griensven; Georgios Pollakis; William A Paxton; Malcolm G Semple
Journal:  Transfusion       Date:  2018-03-23       Impact factor: 3.157

3.  Use of traditional serological methods and oral fluids to assess immunogenicity in children aged 2-16 years after successive annual vaccinations with LAIV.

Authors:  Katja Hoschler; Sunil Maharjan; Heather Whitaker; Jo Southern; Blessing Okai; Janice Baldevarona; Paul J Turner; Nick J Andrews; Elizabeth Miller; Maria Zambon
Journal:  Vaccine       Date:  2020-02-15       Impact factor: 3.641

Review 4.  Ebola virus convalescent blood products: where we are now and where we may need to go.

Authors:  Thierry Burnouf; Jerard Seghatchian
Journal:  Transfus Apher Sci       Date:  2014-10       Impact factor: 1.764

5.  Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone.

Authors:  F Sahr; R Ansumana; T A Massaquoi; B R Idriss; F R Sesay; J M Lamin; S Baker; S Nicol; B Conton; W Johnson; O T Abiri; O Kargbo; P Kamara; A Goba; J B W Russell; S M Gevao
Journal:  J Infect       Date:  2016-11-17       Impact factor: 6.072

Review 6.  Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow.

Authors:  O Garraud; F Heshmati; B Pozzetto; F Lefrere; R Girot; A Saillol; S Laperche
Journal:  Transfus Clin Biol       Date:  2016-01-06       Impact factor: 1.406

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.